Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.56 +0.95 (+1.84%)

Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Is Eli Lilly Stock a Buy? ↗

April 23, 2025

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Via The Motley Fool

Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence ↗

April 22, 2025

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1.

Via Benzinga

Why Novo Nordisk Stock Popped Today ↗

April 22, 2025

Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock.

Via The Motley Fool

Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop ↗

April 22, 2025

Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win.

Via Investor's Business Daily

Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time. ↗

April 22, 2025

Via The Motley Fool

Down 60%, Is This Growth Stock Too Cheap to Ignore? ↗

April 22, 2025

Via The Motley Fool

Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry ↗

April 22, 2025

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results.

Via Stocktwits

Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip? ↗

April 21, 2025

Via The Motley Fool

Did Eli Lilly Just Say Checkmate to Novo Nordisk? ↗

April 21, 2025

Via The Motley Fool

Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy? ↗

April 19, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 18, 2025

Via Benzinga

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.

Via Benzinga

Topics ETFs

Where Will Eli Lilly Be in 5 Years? ↗

April 18, 2025

Via The Motley Fool

Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today ↗

April 17, 2025

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations.

Via Benzinga

Topics Government

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React ↗

April 17, 2025

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Via Benzinga

Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock ↗

April 17, 2025

Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025.

Via Benzinga

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential ↗

April 17, 2025

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by...

Via Benzinga

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide ↗

April 17, 2025

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Via The Motley Fool

Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions' ↗

April 17, 2025

Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs)...

Via Benzinga

Topics Government

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 17, 2025

Via Benzinga

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 17, 2025

Via Benzinga

Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients ↗

April 17, 2025

The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial.

Via Stocktwits

Topics Economy Government Stocks

Eli Lilly Stock Rockets On Weight-Loss Pill Progress ↗

April 17, 2025

Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles.

Via Investor's Business Daily

Topics Government

While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable. ↗

April 17, 2025

Discover NOVO-NORDISK A/S-SPONS ADR, an undervalued growth gem. NYSE:NVO is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...

Via Chartmill

This Microsoft Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

April 17, 2025

Via Benzinga

Viking Therapeutics Stock Pops But Struggles to Hold Gains

April 16, 2025

VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington

Via MarketBeat

Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts ↗

April 15, 2025

FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.

Via Benzinga

Topics Economy

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models ↗

April 15, 2025

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.

Via Benzinga

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch ↗

April 15, 2025

Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition.

Via Benzinga

Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved ↗

April 14, 2025

The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.

Via Stocktwits

Topics Economy

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today